Lung cancer screening - are we there yet?

被引:11
|
作者
Warner, Eiran [2 ]
Jotkowitz, Alan [3 ]
Maimon, Nimrod [1 ]
机构
[1] Soroka Univ, Med Ctr, Dept Med, Pulmonol Inst, Beer Sheva, Israel
[2] Columbia Univ, Med Ctr, Ben Gurion Univ Negev, Med Sch Int Hlth, Beer Sheva, Israel
[3] Soroka Univ, Med Ctr, Dept Med G, Beer Sheva, Israel
关键词
Lung Cancer; Screening; Chest Computed Tomography; Mortality; Survival; Specificity; Sensitivity; COMPUTED-TOMOGRAPHY; SPIRAL CT; FOLLOW-UP; DOSE CT; POPULATION; SURVIVAL; DESIGN; TRIAL; OVERDIAGNOSIS; MORTALITY;
D O I
10.1016/j.ejim.2009.10.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lung cancer is the most lethal cancer and most cases are the result of cigarette smoking. Although a high risk target population for screening can be defined, and although early stage lung cancer has a much better prognosis than advanced disease, there is still no clear evidence that lung cancer screening decreases mortality. Accordingly, current guidelines suggest that there is no evidence to support routine screening. Although randomized studies in the 1970's which used chest x-ray and sputum for screening were clearly negative in the last 20 years more sensitive screening tools such as chest computed tomography have revolutionized the field. However, randomized controlled trials of computed tomography have only recently been launched. Aims of this review: Our objectives are to provide the reader with the rationale for screening for lung cancer, to review the older screening studies and their limitations, and to summarize the current knowledge and ongoing trials of lung cancer screening. Literature search: A literature search using Medline was conducted from 1966 onwards searching for articles with relevant key words such as lung cancer screening chest X - ray low dose computerized tomography cancer screening guideline. When appropriate additional references were found from the bibliographies of identified papers of interest. Conclusions: Recent uncontrolled multicenter studies of chest computed tomography scans show encouraging results. However, until data from, large properly designed and appropriately analyzed randomized controlled trials which may overcome research biases is available, the benefit of lung cancer screening, if any is still unknown. (C) 2009 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 50 条
  • [21] Lung water measurements: Are we there yet?
    Puri, VK
    CRITICAL CARE MEDICINE, 2005, 33 (11) : 2699 - 2700
  • [22] CT screening for lung cancer: so near, yet so far
    Dutt, Naveen
    Hari, Deepak T.
    THORAX, 2012, 67 (07) : 651 - 652
  • [23] Lung Cancer Screening: Where Are We, and How Can We Improve?
    Suzuki, Kei
    Ceppa, DuyKhanh P.
    THORACIC SURGERY CLINICS, 2023, 33 (04) : XIII - XIV
  • [24] Screening for Colorectal Cancer in the Asia-Pacific Region: Are We Ready Yet?
    Sollano, Jose D., Jr.
    Wu, Ming-Shiang
    Sung, Joseph
    NEW CHALLENGES IN GASTROINTESTINAL ENDOSCOPY, 2008, : 273 - +
  • [25] Microfluidics and cancer: are we there yet?
    Zhang, Zhuo
    Nagrath, Sunitha
    BIOMEDICAL MICRODEVICES, 2013, 15 (04) : 595 - 609
  • [26] Microfluidics and cancer: are we there yet?
    Zhuo Zhang
    Sunitha Nagrath
    Biomedical Microdevices, 2013, 15 : 595 - 609
  • [27] Cancer immunotherapy: Are we there yet?
    Li Z.
    Chen L.
    Rubinstein M.P.
    Experimental Hematology & Oncology, 2 (1)
  • [28] Cancer vaccines Are we there yet?
    Hanna, Michael G., Jr.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1161 - 1165
  • [29] SCREENING FOR LUNG-CANCER - WHERE ARE WE NOW
    BAILAR, JC
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1984, 130 (04): : 541 - 542
  • [30] Lung cancer screening in Europe: where are we in 2021?
    van Meerbeeck, Jan P.
    Franck, Caro
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (05) : 2407 - 2417